SELLAS Life Sciences Group Inc
SLSHealthcare|Biotechnology|USA
$12.76
-0.74 (-5.52%)
Tangible Book
$0.58
Earnings Power
$6.03
About
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Stock Price
+573.4%(1Y)
Pipeline Summary
9 total trials3
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
Completed: 6Active: 1Recruiting: 1AVAILABLE: 1
Active Trials (2)
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04229979Acute Myeloid Leukemia
Phase 3Active
Enrollment: 127 participants
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922Hematologic Malignancies
Phase 1Phase 2Recruiting
Enrollment: 160 participants
BioScore
4.5/10
Cautious
Ownership
Recent Insider Trades
Kalin Katherine BachBUY
2025-11-1963,400 shares @ $1.59
VAN NOSTRAND ROBERT LBUY
2025-06-1210,000 shares @ $1.48
Wasman JaneBUY
2025-05-3020,000 shares @ $1.69
Kalin Katherine BachBUY
2025-05-2220,000 shares @ $1.8
Stergiou Angelos M.SELL
2022-12-056,494 shares @ $2.61
Recent News
2026-07-01 14:28:03
2026-06-30 14:29:06
2026-06-29 14:25:45
2026-06-17 13:30:15
2026-06-16 18:00:22
Data last updated: Jul 13, 2026, 12:42 PM